For Healthcare Professionals OnlyPartner Portal
For questions about coronavirus/COVID-19 and using NIOX VERO®, please visit the NIOX VERO Coronavirus/COVID-19 FAQ.
NIOX VERO is one of the most used FeNO testing devices worldwide.1
Asthma’s complexity and heterogeneity means that it’s not always easy to feel confident in diagnosis and management.2 With the prevalence of asthma increasing, poorly controlled asthma can have long term consequences for patients.3,4,5
FeNO testing is now recommended for asthma care in guidelines across the globe.6,7 Having an accurate FeNO testing device is essential in correctly diagnosing and managing asthma. FeNO values are well established and can help to optimise your treatment decision. The current ATS FeNO thresholds7 were derived from trials where NIOX technology was the most widely used device.8 Studies show that results from other FeNO testing devices are not comparable with NIOX and this suggests that NIOX may offer a more reliable reading when managing asthma according to ATS-validated FeNO cut off values.9,10,11,12,13
With unique sensor technology and self-calibration methods, the NIOX VERO is a device that can be trusted
The accuracy of NIOX VERO® is maintained through unique technology that eliminates the impact of environmental NO irrespective of the surroundings and environment.
Once the test have been completed, it takes approximately 1 minute to produce the accurate FeNO result for your patient.
NIOX VERO can also be used to perform nNO tests to help identify and diagnose Primary Ciliary Dyskinesia (PCD) in patients.
NIOX VERO® automatically performs self-checks when the device is switched on. All sensors are individually calibrated during manufacturing to ensure accuracy throughout their stated lifetime without any need to re-calibrate.
Due to variations in sensor technology, other FeNO devices are not directly comparable with NIOX.9,10,11,12,13
NIOX VERO comes from Circassia, the world leader in FeNO testing.
NIOX VERO is easy to use for Healthcare Professionals and patients alike. A choice of three engaging animations along with the optional inclusion of the NIOX Patient and Panel Apps provide the flexibility to tailor the experience as needed. The NIOX VERO device is lightweight and portable allowing easy movement within the clinical setting.
After FeNO measurement, clinicians modified their treatment plan in 31% of cases of which 90% involved changes to ICS medications.2 Studies have also shown up to a 50% reduction in exacerbations where NIOX has been used to regularly test asthma patients in a clinical setting15,16
Want to see how NIOX VERO® could help you accurately diagnose and manage asthma? Fill in the form below.
References: 1. Data on file. Circassia Ltd. October 2019 C-NIOX-0002. 2. Hanania NA et al. Measurement of fractional exhaled nitric oxide in real-world clinical practice alters asthma treatment decisions. Ann Allergy Asthma Immunol. 2018 120(4):414-418. 3. Sears MR. Lung function decline in asthma. Eur Respir J. 2007 30(3):411-3. 4. Bai TR et al. Severe exacerbations predict excess lung function decline in asthma. Eur Respir J. 2007 30(3):452-6. 5. O’Byrne PM et al. Severe exacerbations and decline in lung function in asthma. Am J Respir Crit Care Med. 2009 179(1):19-24. 6. National Institute for Health and Clinical Excellence (NICE). Asthma: diagnosis, monitoring and chronic asthma management. NICE guideline [NG80]. 2017. 7. Dweik RA, Boggs PB, Erzurum SC, et al; on behalf of the American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels (FeNO) for Clinical Applications. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FeNO) for clinical applications. Am J Respir Crit Care Med. 2011;184:602-615. 8. Data on file. Circassia Ltd. October 2019 C-NIOX-0001. 9. Huang T et al. Fractional exhaled nitric oxide measurement: Comparison between the Sunvou-CA2122 analyzer and the NIOX VERO analyzer. J Asthma. 2019 12:1-8. 10. Molino A et al. Comparison of three different exhaled nitric oxide analyzers in chronic respiratory disorders. J Breath Res. 2019 13(2):021002. 11. Saito et al. Comparison of fractional exhaled nitric oxide levels measured by different analyzers produced by different manufacturers. J Asthma. 2019 22:1-11. 12. Kapande KM et al. Comparative repeatability of two handheld fractional exhaled nitric oxide monitors. Pediatr Pulmonol. 2012 47(6):546-50. 13. Tsuburai T et al. Differences in fraction of exhaled nitric oxide values measured by two hand-helded analysers. Arerugi. 2017 66(3):204-208. 14. Alving K et al. Validation of a New Portable Exhaled Nitric Oxide Analyzer, NIOX VERO®: Randomized Studies in Asthma. Pulm Ther. 2017 3(1):207-218. 15. Syk J et al. Anti-inflammatory treatment of atopic asthma guided by exhaled nitric oxide: a randomized, controlled trial. J Allergy Clin Immunol Pract. 2013 1(6):639-48. 16. Petsky H. Exhaled nitric oxide in children with asthma. Respiratory care nurse’s perspective. Indian Pediatr. 2014;51(2):102-103.